---
title: PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated
  stem cell transplantation
date: '2024-03-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38485723/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240315180616&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: There is an increased risk of GVHD and of non-relapse mortality (NRM)
  after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated
  donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte
  globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an
  alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing
  clinical use. It is currently impossible to give general recommendations regarding
  preference ...
disable_comments: true
---
There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing clinical use. It is currently impossible to give general recommendations regarding preference ...